PICO Portalanswers from OpenAlex & ORCID
Mark Lynch
ResearcherPublications, citations & collaboration network
Mark Lynch is a researcher indexed in PICO Portal from OpenAlex & ORCID.
How many works does Mark Lynch have?
PICO Portalindexed works
Mark Lynch has 133 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Mark Lynch have?
PICO Portalcitation count
Mark Lynch has 20,293 citations in the OpenAlex counts PICO Portal stores.
What is the h-index of Mark Lynch?
PICO Portalh-index
Mark Lynch has an h-index of 36 in OpenAlex.
What is the i10-index of Mark Lynch?
PICO Portali10-index
Mark Lynch has an i10-index of 71 in OpenAlex.
What is the ORCID of Mark Lynch?
PICO Portalorcid
The ORCID for Mark Lynch is on the source record.
What is the OpenAlex record for Mark Lynch?
PICO Portalopenalex
The OpenAlex for Mark Lynch is on the source record.
What are the most-cited papers on Mark Lynch?
PICO Portalmost cited works
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, J. Guigay, A. Dimitrios Colevas, Lisa Licitra, Kevin J. Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis P. Worden, Nabil F. Saba, Lara Carmen Iglesias Docampo, Robert I. Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Manish Monga, Mark Lynch, William J. Geese, Justin Kopit, James W. Shaw, Maura L. Gillison
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
Scott M. Wilhelm, Christopher Carter, LiYa Tang, Dean Wilkie, Angela McNabola, Hong Rong, Charles Chen, Xiaomei Zhang, Patrick W. Vincent, Mark McHugh, Yichen Cao, Jaleel Shujath, Susan L. Gawlak, Deepa Eveleigh, Bruce R. Rowley, Li Liu, Lila Adnane, Mark Lynch, Daniel Auclair, I Taylor, Rich Gedrich, Andrei Voznesensky, Bernd Riedl, Leonard Post, Gideon Bollag, Pamela A. Trail
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, J. Guigay, A. Dimitrios Colevas, Lisa Licitra, Kevin J. Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis P. Worden, Nabil F. Saba, Lara Carmen Iglesias Docampo, Robert I. Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Mark Lynch, Vijayvel Jayaprakash, Li Li, Maura L. Gillison